Javascript must be enabled to continue!
Regulation of microRNAs on cellular expression levels of myocardial angiotensin-converting enzyme
View through CrossRef
Objective
To investigate the regulation of microRNAs (generally shorten as miRNAs) on the expression levels of angiotensin-converting enzyme (ACE), which is a key candidate gene in cerebrovascular and cardiovascular diseases. Methods Around 37 miRNAs that may regulate ACE were predicted based on the ‘eed-region’ principle. Among them, miR-27a and miR-27b are two ACE-regulating miRNAs matching 3'-UTR regions of both human and rodent origin and thereby were the focus of further tests. Rat myocardial cell line H9c2 (2-1) in culture was subjected to miR-27a and 27b enhancing and inhibiting treatments. MiR-27a and 27b precursor molecules were applied to boost the functional levels, while chemically modified miR-27a and 27b as antagonists were applied to blunt the activities of miR-27a and 27b, respectively. Each test was controlled with the treatment using corresponding negative control molecules. The precursor and inhibitor were introduced into cells using iFect mediated transfection. Cells were harvested for ACE immunoblotting after 48 h of treatments.
Results
Enhancing of miR-27a or 27b with corresponding precursors significantly down-regulated cellular ACE protein levels, while inhibiting with corresponding antagonists significantly up-regulated ACE levels. According to ANOVA analysis, 48 hours treatments of miR-27a and miR-27b precursors reduced ACE levels by 35.98% (p=0.022) and 41.32% (p=0.009), respectively; meanwhile, 48 h treatments of miR-27a and miR-27b antagonists increased ACE levels by 46.11% (p=0.047) and 75.15% (p=0.002), respectively.
Conclusion
miR-27a and miR-27b significantly regulate myocardial ACE levels in a negatively correlated pattern.
Title: Regulation of microRNAs on cellular expression levels of myocardial angiotensin-converting enzyme
Description:
Objective
To investigate the regulation of microRNAs (generally shorten as miRNAs) on the expression levels of angiotensin-converting enzyme (ACE), which is a key candidate gene in cerebrovascular and cardiovascular diseases.
Methods Around 37 miRNAs that may regulate ACE were predicted based on the ‘eed-region’ principle.
Among them, miR-27a and miR-27b are two ACE-regulating miRNAs matching 3'-UTR regions of both human and rodent origin and thereby were the focus of further tests.
Rat myocardial cell line H9c2 (2-1) in culture was subjected to miR-27a and 27b enhancing and inhibiting treatments.
MiR-27a and 27b precursor molecules were applied to boost the functional levels, while chemically modified miR-27a and 27b as antagonists were applied to blunt the activities of miR-27a and 27b, respectively.
Each test was controlled with the treatment using corresponding negative control molecules.
The precursor and inhibitor were introduced into cells using iFect mediated transfection.
Cells were harvested for ACE immunoblotting after 48 h of treatments.
Results
Enhancing of miR-27a or 27b with corresponding precursors significantly down-regulated cellular ACE protein levels, while inhibiting with corresponding antagonists significantly up-regulated ACE levels.
According to ANOVA analysis, 48 hours treatments of miR-27a and miR-27b precursors reduced ACE levels by 35.
98% (p=0.
022) and 41.
32% (p=0.
009), respectively; meanwhile, 48 h treatments of miR-27a and miR-27b antagonists increased ACE levels by 46.
11% (p=0.
047) and 75.
15% (p=0.
002), respectively.
Conclusion
miR-27a and miR-27b significantly regulate myocardial ACE levels in a negatively correlated pattern.
Related Results
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Introduction:
The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure, water- and electrolyte balance. Pathophysiologically,...
PO-273 Exercise, myocardial insulin resistance and myostatin
PO-273 Exercise, myocardial insulin resistance and myostatin
Objective Myostatin (MSTN) is a member of the TGF-β superfamily and is a negative regulator of skeletal muscle growth. MSTN is also expressed in other tissues such as heart and fa...
The mechanism of oxidative stress in keloid fibroblasts and the experimental study of early application of angiotensin-converting enzyme inhibitor
The mechanism of oxidative stress in keloid fibroblasts and the experimental study of early application of angiotensin-converting enzyme inhibitor
Objective
To investigate the protective effects of an angiotensin-converting enzyme inhibitor after inducing oxidative stress on keloid fibroblasts.
Methods
Primary keloid fibrob...
Angiotensin II Induces Oxidative Stress in Prostate Cancer
Angiotensin II Induces Oxidative Stress in Prostate Cancer
Abstract
Angiotensin II has been shown to be a cytokine especially acting as a growth factor. A local renin-angiotensin system has been identified in the prostate gl...
Studi Literatur Potensi Beberapa Ekstrak Tumbuhan Mengandung Katekin sebagai Antihipertensi
Studi Literatur Potensi Beberapa Ekstrak Tumbuhan Mengandung Katekin sebagai Antihipertensi
Abstract. High blood pressure or hypertension is one of the risks of cardiovascular disease with a high prevalence of death. Hypertension is a condition in which blood pressure exc...
The CML-Microvesicles Are Enriched with Mirnas Regulating MAPK Signaling Pathway.
The CML-Microvesicles Are Enriched with Mirnas Regulating MAPK Signaling Pathway.
Abstract
Abstract 2786
Leukemia-cell-derived microvesicles (MVs) act as vehicles for exchange of genetic information between leukemia and nomal cells,...
Simultaneous Determination of Plasma Converting Enzyme and Angiotensinase Activity by Radioimmunoassay
Simultaneous Determination of Plasma Converting Enzyme and Angiotensinase Activity by Radioimmunoassay
1. Homologous angiotensin-I was added to untreated plasma. Angiotensin-II which is formed by plasma converting enzyme and subsequently degradated by angiotensinases was determined ...

